Can nanoparticles and nano‒protein interactions bring a bright future for insulin delivery?

Abstract

Insulin therapy plays an essential role in the treatment of diabetes mellitus. However, frequent injections required to effectively control the glycemic levels lead to substantial inconvenience and low patient compliance. In order to improve insulin delivery, many efforts have been made, such as developing the nanoparticles (NPs)-based release systems and oral insulin. Although some improvements have been achieved, the ultimate results are still unsatisfying and none of insulin-loaded NPs systems have been approved for clinical use so far. Recently, nano‒protein interactions and protein corona formation have drawn much attention due to their negative influence on the in vivo fate of NPs systems. As the other side of a coin, such interactions can also be used for constructing advanced drug delivery systems. Herein, we aim to provide an insight into the advance and flaws of various NPs-based insulin delivery systems. Particularly, an interesting discussion on nano‒protein interactions and its potentials for developing novel insulin delivery systems is initiated.

Virus-Mimicking Mesoporous Silica Nanoparticles with an Electrically Neutral and Hydrophilic Surface to Improve the Oral Absorption of Insulin by Breaking Through Dual Barriers of the Mucus Layer and the Intestinal Epithelium

“…Designing protein or peptide drugs for oral delivery still remains challenging due to multiple barriers. − The first is the acidity of the gastrointestinal tract and the abundant peptidases and proteases, fully responsible for the degradation of protein drugs. , To stabilize protein drugs, researchers usually chemically modify the protein sites susceptible to enzymes, coadminister proteins and protease inhibitors, or encapsulate proteins into liposomes, polymer nanoparticles, or micelles. , Among them, loading proteins through mesoporous silica nanoparticles (MSNs) are especially superior for their excellent physiochemical stability, good biocompatibility, ability to protect proteins from degradation, and high drug loading due to large surface area (>700 m 2 /g), large pore volume (>1 cm 3 /g), and adjustable pore size (2–10 nm) . Furthermore, different functional groups can be modified on the MSN surface with silanol groups. , …”

Exosomal targeting and its potential clinical application

“…As a nanoparticle carrier for drug delivery, exosomes still face different challenges in the clinical treatment of diseases. In recent years, the effects of nano protein interaction and the formation of protein corona (PC) on the transport fate of nano carriers have been confirmed [144,145]. The formation of protein corona is affected by many factors, mainly including the physical and chemical properties of nanoparticles and nanoparticles (NPs) exposure concentration.…”

Recent Advances in Nanomedicines for Multiple Sclerosis Therapy

“…Due to rapid development in nanomaterials and nanotechnology, many nanomedicines have been or will be able to be translated for clinical use. ,− Treatment of MS with its complex pathogenic mechanisms is bottlenecked with delivering therapeutic agents, targeting disease tissues/cells, tracking implanted cells, and promoting remyelination. These bottlenecks may be overcome through these advances in nanomaterials and nanotechnology.…”